BioNTech and Pfizer have already sold part of the planned production of a vaccine against SARS-CoV-2 that is currently under development. Britain will receive 30 million doses of vaccine, the Mainz biotech company and its US partner company announced on Monday. No details are given of the financial details of the arrangement with the UK government. The doses against the causative agent of the Covid-19 pandemic, which has been raging for months, are expected to be administered in 2020 and 2021, subject to regulatory approval or approval, according to BioNTech and Pfizer.
“Pfizer and BioNTech remain on track to begin an expected phase 2b / 3 safety and efficacy study later this month, to seek regulatory review as early as October 2020, and up to 100 million doses worldwide by the end of 2020 and by the end of 2021 to manufacture more than 1.3 billion cans, ”says the two companies. Most recently BioNTech and Pfizer Good data from a phase 1/2 clinical trial for BNT162 vaccine against SARS-CoV-2 corona virus announced. In addition, data from the German arm of the study will be announced later this month.
It shouldn’t be the last of this kind from BioNTech and Pfizer: “We are in advanced talks with numerous other government agencies and hope to be able to announce further delivery agreements soon. Our goal remains to provide a safe and effective vaccine against COVID-19 to as many people around the world as possible, ”said Ugur Sahin, CEO and co-founder of BioNTech.
The further schedule is tight. If the studies are successful, both companies want to apply for a conditional market approval or some form of official approval in October. With a quick approval for BNT162 is to be expected in this case. 100 million doses of vaccine are expected to be produced by the end of 2020, and possibly more than 1.3 billion doses by the end of 2021.
BioNTech’s share price this morning is around 76.50 / 77.00 euros for indications.
More about biotech shares on 4investors: click here
At a glance – chart and news: BioNTech